Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-05
2008-05-20
Seaman, Margaret D. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S345000
Reexamination Certificate
active
07375112
ABSTRACT:
The present invention provides a method of administering vitamin B6 related compounds for treatment of hypertriglyceridemia. Vitamin B6 related compounds include pyridoxal, pyridoxal-5′-phosphate, pyridoxamine, a 3-acylated analogue of pyridoxal, a 3-acylated analogue of pyridoxal-4,5-aminal, and mixtures thereof. Embodiments of the present invention also comprise co-administering a lipid lowering agent, such as a nicotinic acid, a fibrate, a HMG CoA reductase inhibitor, a cholesteryl ester transfer protein inhibitor, and combinations thereof.
REFERENCES:
patent: 2918471 (1959-12-01), Mowat et al.
patent: 3282778 (1966-11-01), Lobel
patent: 3573286 (1971-03-01), Zenno et al.
patent: 5130252 (1992-07-01), Eck et al.
patent: 6043259 (2000-03-01), Dhalla et al.
patent: 6051587 (2000-04-01), Dakashinamurti et al.
patent: 6339085 (2002-01-01), Haque
patent: 6417204 (2002-07-01), Haque
patent: 6489345 (2002-12-01), Sethi et al.
patent: 6548519 (2003-04-01), Haque
patent: 6585414 (2003-07-01), Peska
patent: 6586414 (2003-07-01), Haque et al.
patent: 6605612 (2003-08-01), Haque
patent: 6667315 (2003-12-01), Haque
patent: 6677356 (2004-01-01), Sethi et al.
patent: 6780997 (2004-08-01), Haque
patent: 6861439 (2005-03-01), Haque et al.
patent: 6867215 (2005-03-01), Haque
patent: 6890943 (2005-05-01), Haque
patent: 6897228 (2005-05-01), Haque
patent: 7105673 (2006-09-01), Haque
patent: 7115625 (2006-10-01), Sethi et al.
patent: 7115626 (2006-10-01), Sethi et al.
patent: 7125889 (2006-10-01), Sethi et al.
patent: 7132430 (2006-11-01), Sethi et al.
patent: 7144892 (2006-12-01), Sethi et al.
patent: 7148233 (2006-12-01), Sethi et al.
patent: 7230009 (2007-06-01), Haque et al.
patent: 2001/0056081 (2001-12-01), Haque et al.
patent: 2003/0114424 (2003-06-01), Haque et al.
patent: 2004/0038945 (2004-02-01), Sethi et al.
patent: 2004/0121988 (2004-06-01), Haque et al.
patent: 2004/0171588 (2004-09-01), Haque
patent: 2004/0186077 (2004-09-01), Diakur et al.
patent: 2004/0235907 (2004-11-01), Sethi
patent: 2005/0107443 (2005-05-01), Haque
patent: 2006/0019929 (2006-01-01), Friesen
patent: 2006/0035864 (2006-02-01), Friesen
patent: 2006/0094748 (2006-05-01), Haque et al.
patent: 2006/0094749 (2006-05-01), Haque et al.
patent: 2006/0094761 (2006-05-01), Haque et al.
patent: 2006/0241083 (2006-10-01), Diakur et al.
patent: 2007/0032456 (2007-02-01), Friesen
patent: 2007/0060549 (2007-03-01), Friesen
patent: 2007/0142270 (2007-06-01), Haque et al.
patent: 2007/0149485 (2007-06-01), Friesen
patent: 2007/0167411 (2007-07-01), Reimer
patent: 2007/0243249 (2007-10-01), Reimer
patent: 2007/0249562 (2007-10-01), Reimer
patent: 2717478 (1978-11-01), None
patent: 4344751 (1995-06-01), None
patent: 45011700 (1970-04-01), None
patent: 45015984 (1970-06-01), None
patent: 45016218 (1970-06-01), None
patent: 45016711 (1970-06-01), None
patent: 45016712 (1970-06-01), None
patent: 47003830 (1972-02-01), None
patent: 2004/084895 (2004-07-01), None
patent: 2004/084910 (2004-07-01), None
patent: WO 2005/060975 (2005-07-01), None
patent: WO 2006/005173 (2006-01-01), None
patent: WO 2006/026868 (2006-03-01), None
patent: WO 2006/056079 (2006-06-01), None
patent: WO 2006/058411 (2006-06-01), None
patent: WO 2006/102748 (2006-10-01), None
Aguilar-Salinas et l., “Prevalence and characteristics of early-onset type 2 diabetes in mexico”, American Journal of Medicine, 2002, vol. 113, pp. 569-574.
Harada et al., “Vitamin B6. V. Behavior of orally administered pyridoxal acylates in the blood”, Bitamin, 1972, vol. 45, pp. 76-80.
Harada et al., “Vitamin B6. IV. behavior of pyridoxal acylates in the body after parenteral administration”, Bitamin, 1972, vol. 45, pp. 69-75, abstract only see CA 1972: 428787 (AN 77:28747).
Heyl et al., “phosphates of the vitamin B6 group. II. 3-pyridoxalphosphoric acid”, Journal of the american chemistry society, 1951, vol. 73, pp. 3434-3436.
Heyl et al., “phosphates of the vitamin B6 group. I. The structure of codecarboxylase”, Journal of the american chemical society, 1951, vol. 73, pp. 3430-3433.
Assmann et al., “Relation of High-Density Lipoprotein Cholesterol and Triglycerides to Incidence of Atherosclerotic Coronary Artery Disease (The PROCAM Experience)” Journal of American Cardiology 70 (1992) p. 733-737.
Assmann et al., “Genetic (Primary) Forms of Hypertriglyceridemia” The American Journal of Cardiology. vol. 68 (1991) p. 13a-16a.
Attman et al., “Lipid Abnormalities in Progressive Renal Insufficiency” Contrib. Nephrol. vol. 120 (1997) p. 1-10.
Austin et al., “Hypertriglyceridemia as a Cardiovascular Risk Factor” American Journal of Cardiology 81(4A) (1998) p. 7B-12B.
Berge et al., “Pharmaceutical Salts” Journal of Pharmaceutical Sciences vol. 66, No. 1 (1997) p. 1-19.
Coughlan et al., “Does hyperglyceridemia increase risk for CAD? Growing evidence suggests it plays a role” Postgraduate Medicine vol. 108 No. 7 (2000) p. 77-84.
Di Martino et al., “Severe acute pancreatitis related to the use fo nelfinavir in HIV infection: report of a case with positive rechallange” AIDS vol. 13 No. 11 (1999) p. 1421-1423.
Elisaf et al., “Tamoxifen-induced severe hypertriglyceridemia and pancreatitis” Annals of Oncology 11: (2000) p. 1067-1069.
Fogari et al., “Plasma Lipids During Chronic Antihypertensive Therapy with Different β-Blockers” Journal of Cardiovascular Pharmacology 14 (Suppl. 7) (1989) p. 328-332.
Gaulin et al., “Clozapine-Associated Elevation in Serum Triglycerides” American Journal of Psychiatry 156:8 (Aug. 1999) p. 1270-1272.
Gaspard et al., “A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles” Contraception 69 (2004) p. 271-278.
Greene et al., “Hyperlipidemia and fatty acid composition in patients treated for type IA glycogen storage disease” Journal of Pediatrics, vol. 119 No. 3 (1991) p. 398-403.
Groth et al., “Sirolimus (Rapamycin)-Based Therapy in Human Renal Transplantation, Similar Efficacy and Different Toxicity Compared with Cyclosporine” Transplantation, vol. 67 No. 7 (Apr. 1999) p. 1036-1042.
Jeppesen et al., “Triglyceride Concentration and Ischemic Heart Disease, An Eight Year Follow-up in the Copenhagen Male Study” Circulation 97 (1998) p. 1029-1036.
Kreisberg., “Diabetic Dyslipidemia” The American Journal of Cardiology vol. 82 (12A) (1998) p. 67U-73U.
Kvetny et al., “Subclinical hypothyroidism is associated with a low-grade inflammation, increased trygliceride levels and predicts cardiovascular disease in males below 50 years” Clinical Endocrinology 61 (2004) p. 232-238.
Lindholm et al., “Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE Study)” Journal of Hypertension vol. 21 No. 8 (2003) p. 1563-1574.
Mancini et al., “Acquired (Secondary) Forms of Hypertriglyceridemia” The American Journal of Cardiology vol. 68, (Jul. 1991) p. 17A-21A.
Mantel-Teeuwisse et al. “Drug-Induced Lipid Changes, A review of the Unintended Effects of Some Commonly Used Drugs on Serum Lipid Levels” Drug Safety 24 (6) (2001) p. 443-456.
Matteucci et al., “An Early Diagnosis of Kidney Involvement in Immunologically-mediated Multisystem Diseases” Clinical Rheumatology 15, No. I (1996) p. 20-24.
Miller et al., “Quantitative and Qualitative Changes in Lipids, Lipoproteins, Apolipoprotein A-I, and Sex Hormone-Binding Globulin Due to Two Doses of Conjugated Equine Estrogen With and Without a Progestin” Obstetrics & Gynecology vol. 83, No. 2 (Feb. 1994) p. 173-179.
Mirete et al., “Acute Pancreatitis as a Complication of Ritonavir Therapy in a Patient with AIDS” Euro
Friesen Albert D.
Zettler Marjorie
Medicure International Inc.
Merchant & Gould P.C.
Rahmani Niloofar
Seaman Margaret D.
LandOfFree
Compounds and methods for regulating triglyceride levels does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for regulating triglyceride levels, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for regulating triglyceride levels will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3987374